The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Clonal evolution of chemotherapy-resistant urothelial carcinoma
Open accessAbstract
Chemotherapy-resistant urothelial carcinoma has no uniformly curative therapy. Understanding how selective pressure from chemotherapy directs the evolution of urothelial carcinoma and shapes its clonal architecture is a central biological question with clinical implications. To address this question, we performed whole-exome sequencing and clonality analysis of 72 urothelial carcinoma samples, including 16 matched sets of primary and advanced tumors prospectively collected before and after chemotherapy. Our analysis provided several insights: (i) chemotherapy-treated urothelial carcinoma is characterized by intra-patient mutational heterogeneity, and the majority of mutations are not shared; (ii) both branching evolution and metastatic spread are very early events in the natural history of urothelial carcinoma; (iii) chemotherapy-treated urothelial carcinoma is enriched with clonal mutations involving L1 cell adhesion molecule (L1CAM) and integrin signaling pathways; and (iv) APOBEC-induced mutagenesis is clonally enriched in chemotherapy-treated urothelial carcinoma and continues to shape the evolution of urothelial carcinoma throughout its lifetime.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Comprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
Mutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909
von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.757 · Cited by 1,850
The Parsimony Ratchet, a New Method for Rapid Parsimony Analysis
Nixon, K. (1999) · Cladistics · doi:10.1006/clad.1999.0121 · Cited by 1,773
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
Self-citationEnsembl BioMarts: a hub for data retrieval across taxonomic space
Kinsella, R. J., Kahari, A., Haider, S., Zamora, J., Proctor, G., Spudich, G., Almeida-King, J., Staines, D., Derwent, P., Kerhornou, A., et al. (2011) · Database · doi:10.1093/database/bar030 · Cited by 1,437
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles, M. A., & Hurst, C. D. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3817 · Cited by 1,247
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
Roberts, S. A., Lawrence, M. S., Klimczak, L. J., Grimm, S. A., Fargo, D., Stojanov, P., Kiezun, A., Kryukov, G. V., Carter, S. L., Saksena, G., et al. (2013) · Nature Genetics · doi:10.1038/ng.2702 · Cited by 1,167
The Sequence Ontology: a tool for the unification of genome annotations
Eilbeck, K., Lewis, S. E., Mungall, C. J., Yandell, M., Stein, L., Durbin, R., & Ashburner, M. (2005) · Genome Biology · doi:10.1186/gb-2005-6-5-r44 · Cited by 806
Bellmunt, J., Théodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., Caty, A., Carles, J., Jagiello-Gruszfeld, A., Karyakin, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5534 · Cited by 766
Sethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C., Salter, D., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Strieter, R., et al. (1999) · Nature Medicine · doi:10.1038/9511 · Cited by 739
Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance
Seguin, L., Desgrosellier, J. S., Weis, S. M., & Cheresh, D. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.12.006 · Cited by 685
Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells
Zellweger, R., Dalcher, D., Mutreja, K., Berti, M., Schmid, J. A., Herrador, R., Vindigni, A., & Lopes, M. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201406099 · Cited by 677
Tetraspanins: push and pull in suppressing and promoting metastasis
Zöller, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2543 · Cited by 663
Retroviral restriction by APOBEC proteins
Harris, R. S., & Liddament, M. T. (2004) · Nature Reviews Immunology · doi:10.1038/nri1489 · Cited by 654
Sternberg, C. N., de Mulder, P. H. M., Schornagel, J. H., Théodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, F., Spina, M., van Groeningen, C. J., de Balincourt, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2638 · Cited by 628
Self-citationSomatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
Van Allen, E. M., Mouw, K. W., Kim, P., Iyer, G., Wagle, N., Al-Ahmadie, H., Zhu, C., Ostrovnaya, I., Kryukov, G. V., O'Connor, K. W., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0623 · Cited by 620
Self-citationSternberg, C. N., de Mulder, P., Schornagel, J. H., Theodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, J. A., Spina, M., van Groeningen, C. J., Duclos, B., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.032 · Cited by 542
Self-citationPlimack, E. R., Dunbrack, R. L., Brennan, T. A., Andrake, M. D., Zhou, Y., Serebriiskii, I. G., Slifker, M., Alpaugh, K., Dulaimi, E., Palma, N., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.009 · Cited by 519
Oncotator: Cancer Variant Annotation Tool
Ramos, A. H., Lichtenstein, L., Gupta, M., Lawrence, M. S., Pugh, T. J., Saksena, G., Meyerson, M., & Getz, G. (2015) · Human Mutation · doi:10.1002/humu.22771 · Cited by 501
Chan, K., Roberts, S. A., Klimczak, L. J., Sterling, J. F., Saini, N., Malc, E. P., Kim, J., Kwiatkowski, D. J., Fargo, D. C., Mieczkowski, P. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3378 · Cited by 414
Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors
Kim, J., Mouw, K. W., Polak, P., Braunstein, L. Z., Kamburov, A., Tiao, G., Kwiatkowski, D. J., Rosenberg, J. E., Van Allen, E. M., D'Andrea, A. D., et al. (2016) · Nature Genetics · doi:10.1038/ng.3557 · Cited by 413
Self-citationHypermutation in human cancer genomes: footprints and mechanisms
Roberts, S. A., & Gordenin, D. A. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3816 · Cited by 405
Signalling via integrins: Implications for cell survival and anticancer strategies
Hehlgans, S., Haase, M., & Cordes, N. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.09.001 · Cited by 373
Focal adhesion signaling and therapy resistance in cancer
Eke, I., & Cordes, N. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.07.009 · Cited by 330
Clark, P. E., Agarwal, N., Biagioli, M. C., Eisenberger, M. A., Greenberg, R. E., Herr, H. W., Inman, B. A., Kuban, D. A., Kuzel, T. M., Lele, S. M., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0059 · Cited by 317
Rubio-Perez, C., Tamborero, D., Schroeder, M. P., Antolín, A. A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Perez, A., & Lopez-Bigas, N. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.007 · Cited by 296
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response
Beltran, H., Eng, K., Mosquera, J. M., Sigaras, A., Romanel, A., Rennert, H., Kossai, M., Pauli, C., Faltas, B., Fontugne, J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1313 · Cited by 288
Self-citationLiu, D., Plimack, E. R., Hoffman-Censits, J., Garraway, L. A., Bellmunt, J., Van Allen, E., & Rosenberg, J. E. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1056 · Cited by 259
Self-citationCancer Evolution and the Limits of Predictability in Precision Cancer Medicine
Lipinski, K. A., Barber, L. J., Davies, M. N., Ashenden, M., Sottoriva, A., & Gerlinger, M. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2015.11.003 · Cited by 248
L1CAM: A major driver for tumor cell invasion and motility
Kiefel, H., Bondong, S., Hazin, J., Ridinger, J., Schirmer, U., Riedle, S., & Altevogt, P. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20832 · Cited by 227
APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication
Hoopes, J. I., Cortez, L. M., Mertz, T. M., Malc, E. P., Mieczkowski, P. A., & Roberts, S. A. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.021 · Cited by 223
Voura, E. B., Ramjeesingh, R. A., Montgomery, A. M. P., & Siu, C.-H. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.9.2699 · Cited by 199
Targeting FAK in human cancer: from finding to first clinical trials
Golubovskaya, V. (2014) · Frontiers in Bioscience · doi:10.2741/4236 · Cited by 195
Meier, B., Cooke, S. L., Weiss, J., Bailly, A. P., Alexandrov, L. B., Marshall, J., Raine, K., Maddison, M., Anderson, E., Stratton, M. R., et al. (2014) · Genome Research · doi:10.1101/gr.175547.114 · Cited by 191
A comprehensive survey of the mutagenic impact of common cancer cytotoxics
Szikriszt, B., Póti, Á., Pipek, O., Krzystanek, M., Kanu, N., Molnár, J., Ribli, D., Szeltner, Z., Tusnády, G. E., Csabai, I., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-0963-7 · Cited by 181
Lee, Y.-S., Gregory, M. T., & Yang, W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324001111 · Cited by 167
Hazlehurst, L. A., & Dalton, W. S. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013156407224 · Cited by 162
Hodkinson, P. S., Elliott, T., Wong, W. S., Rintoul, R. C., MacKinnon, A. C., Haslett, C., & Sethi, T. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401849 · Cited by 144
New Therapeutic Challenges in Advanced Bladder Cancer
Joaquim Bellmunt, B., & Petrylak, D. P. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.08.007 · Cited by 127
Müerköster, S. S., Werbing, V., Sipos, B., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1210076 · Cited by 122
Shain, K. H., & Dalton, W. S. (2001) · PubMed · Cited by 117
Integrins as Novel Drug Targets for Overcoming Innate Drug Resistance
Damiano, J. S. (2002) · Current Cancer Drug Targets · doi:10.2174/1568009023334033 · Cited by 110
Unraveling the clonal hierarchy of somatic genomic aberrations
Prandi, D., Baca, S. C., Romanel, A., Barbieri, C. E., Mosquera, J., Fontugne, J., Beltran, H., Sboner, A., Garraway, L. A., Rubin, M. A., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0439-6 · Cited by 104
Self-citationStoeck, A., Gast, D., Sanderson, M. P., et al. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.08.038 · Cited by 95
Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer
Schultze, A., & Fiedler, W. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.489548 · Cited by 94
Greco, C., Bralet, M., Ailane, N., Dubart‐Kupperschmitt, A., Rubinstein, E., Naour, F. L., & Boucheix, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4482 · Cited by 92
APOBEC3B and AID Have Similar Nuclear Import Mechanisms
Lackey, L., Demorest, Z. L., Land, A. M., Hultquist, J. F., Brown, W. L., & Harris, R. S. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.03.011 · Cited by 91
SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines
Demichelis, F., Greulich, H. E., Macoska, J. A., Beroukhim, R., Sellers, W. R., Garraway, L. A., & Rubin, M. A. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn089 · Cited by 75
Self-citationRezaee, M., Sanche, L., & Hunting, D. J. (2013) · Radiation Research · doi:10.1667/rr3185.1 · Cited by 73
Argyris, E. G., Acheampong, E. A., Wang, F., Huang, J., Chen, K., Mukhtār, M., & Zhang, H. (2007) · Virology · doi:10.1016/j.virol.2007.06.010 · Cited by 70
Zhang, H., Ozaki, I., Mizuta, T., Matsuhashi, S., Yoshimura, T., Hisatomi, A., Tadano, J., Sakai, T., & Yamamoto, K. (2002) · Cancer · doi:10.1002/cncr.10751 · Cited by 68
ASEQ: fast allele-specific studies from next-generation sequencing data
Romanel, A., Lago, S., Prandi, D., Sboner, A., & Demichelis, F. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0084-2 · Cited by 63
Self-citationFOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis
van Boxtel, R., Gomez‐Puerto, M. C., Mokrý, M., Eijkelenboom, A., van der Vos, K. E., Nieuwenhuis, E. E. S., Burgering, B. M. T., Lam, E. W. ‐., & Coffer, P. J. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.81 · Cited by 56
TSPAN8 promotes gastric cancer growth and metastasis via ERK MAPK pathway.
Wei, L., Li, Y., & Suo, Z. (2015) · Europe PMC (PubMed Central) · Cited by 52
Genome-Wide Detection of Genes Targeted by Non-Ig Somatic Hypermutation in Lymphoma
Jiang, Y., Soong, T. D., Wang, L., Melnick, A. M., & Elemento, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040332 · Cited by 52
Self-citationStochastic properties of processive cytidine DNA deaminases AID and APOBEC3G
Chelico, L., Pham, P., & Goodman, M. F. (2008) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2008.0195 · Cited by 50
L1 Cell Adhesion Molecule Is a Novel Therapeutic Target in Intrahepatic Cholangiocarcinoma
Min, J., Kim, J., Li, S., Lee, J. W., Yoon, H., Ryu, C. J., Jeon, S. H., Lee, J.-H., Kim, J. Y., Yoon, H. K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3075 · Cited by 45
L1-CAM as a target for treatment of cancer with monoclonal antibodies.
Weidle, U. H., Eggle, D., & Klostermann, S. (2009) · PubMed · Cited by 44
Burgett, M. E., Lathia, J. D., Roth, P., Nowacki, A. S., Galileo, D. S., Pugacheva, E. N., Huang, P., Vasanji, A., Li, M., Byzova, T. V., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9700 · Cited by 38
Identification of Pold2 as a novel interaction partner of protein inhibitor of activated STAT2
Zheng, Y., Sheng, S., Wang, H., Jia, X., Hu, Y., Qian, Y., Zhu, Y., & Wang, J. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1065 · Cited by 5
Cited by
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K., Chua, C. W., Barlow, L. J., Kandoth, C., Williams, A. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.017 · Cited by 873
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Pan-cancer whole-genome comparison of primary and metastatic solid tumours
Martínez-Jiménez, F., Movasati, A., Brunner, S. R., Nguyen, L., Priestley, P., Cuppen, E., & Van Hoeck, A. (2023) · Nature · doi:10.1038/s41586-023-06054-z · Cited by 285
Metadata
- Authors
- Faltas, B. M., Prandi, D., Tagawa, S. T., Molina, A. M., Nanus, D. M., Sternberg, C., Rosenberg, J., Mosquera, J. M., Robinson, B., Elemento, O., Sboner, A., Beltran, H., Demichelis, F., & Rubin, M. A.
- Venue
- Nature Genetics
- Published
- 2016-10-17
- Volume
- 48
- Issue
- 12
- Pages
- 1490-1499
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2533194337
- Cited by
- 294
- References
- 64
- FWCI
- 12.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.